Veru is trading 5.2% down at $2.67 today as the stock undergoes profit-taking and consolidation following its recent sharp rally.
- The previous multi-day surge was driven by a clinical supply agreement with Novo Nordisk and stronger-than-expected Q2 fiscal 2026 results.
- Today's decline follows recent gains of 10.7%, with no new company-specific headlines or broader market catalysts driving the downward move.